Browse the evidence

Cagrilintide-Semaglutide (CagriSema) produces superior weight loss and metabolic improvements compared to monotherapies and placebo in adults with overweight or obesity, with or without type 2 diabetes.

CagriSema is a potent, non-surgical weight loss option that significantly outperforms current GLP-1 monotherapies. It requires weekly (implied) injections and lifestyle changes. Expect transient GI side effects that usually subside. It is suitable for those with BMI ≥30 (or ≥27 with comorbidities), including those with T2D.

Liraglutide 3 mg daily induces significant weight loss in adults with obesity by slowing gastric emptying of solids and increasing satiation, with greater gastric emptying delay correlating with greater weight loss.

Take liraglutide 3 mg daily as prescribed, starting with a lower dose to minimize side effects. Expect some nausea initially, as this often signals the drug is working and may lead to greater weight loss. Combine with dietary counseling for best results. The medication works by slowing digestion and making you feel full sooner, helping you eat less.

Tirzepatide produces the greatest weight loss and superior cardiometabolic improvements (blood pressure, triglycerides, glucose) among FDA/EMA-approved anti-obesity medications.

If you have obesity and comorbidities, Tirzepatide is currently the most effective FDA-approved medication for weight loss and improving metabolic markers like blood pressure and blood sugar. It outperforms Semaglutide in weight reduction magnitude.

Tirzepatide significantly reduces body weight, BMI, and waist circumference in overweight or obese adults without diabetes compared to placebo.

If you are overweight or obese and do not have diabetes, tirzepatide is a highly effective prescription medication for significant weight loss. It is taken once a week by injection. While it causes side effects like nausea and vomiting in many people, the weight loss benefits are substantial. You should discuss the risks and benefits with your doctor and start with a low dose to minimize side effects.

Time-restricted eating (TRE) significantly reduces body weight and fasting insulin levels in overweight and obese women compared to control groups, without negatively affecting fat-free or lean body mass.

If you are overweight or obese, try restricting your eating window to 8-10 hours a day (e.g., 10 AM to 6 PM). This approach has been shown to help women lose weight and improve insulin sensitivity without losing muscle mass, and it is often easier to stick to than strict calorie counting.

Lactobacillus sp. probiotic supplementation significantly reduces body mass index, body weight, waist and hip circumference, and visceral/subcutaneous fat mass in non-comorbid obese individuals compared to placebo.

If you are obese without other major health conditions, adding a Lactobacillus probiotic (doses ranging from 1 million to 50 billion CFU daily) to your routine may help reduce body weight, BMI, and waist circumference. The effect is modest but statistically significant, particularly when taken for at least 12 weeks. It is not a magic bullet but may support other lifestyle changes.

In adults with obesity without diabetes, tirzepatide produces significantly greater weight loss and cardiometabolic improvements than semaglutide over 6 months, even when semaglutide patients receive higher maintenance doses.

If you are choosing between tirzepatide and semaglutide for obesity management without diabetes, tirzepatide offers greater weight loss and better cardiometabolic improvements over 6 months. This advantage holds true even if you are on a higher maintenance dose of semaglutide than the typical tirzepatide dose. Consult your doctor to determine which medication aligns best with your health profile and insurance coverage.

Six months of intermittent fasting (2-3 non-consecutive days of vegetable-only fasting per week) significantly reduces body weight, body fat, and improves lipid profiles (LDL-C, non-HDL-C, triglycerides) in middle-aged adults with overweight, without significantly affecting blood pressure, fasting glucose, or inflammatory markers.

If you are overweight and middle-aged, trying intermittent fasting 2-3 days a week with a vegetable-only diet on those days can significantly improve your weight and cholesterol levels without needing to change your diet on other days. This approach is well-tolerated and offers specific metabolic benefits beyond just eating less.

Flexible time-restricted eating combined with aerobic exercise improves insulin resistance (HOMA-IR) and insulin levels more effectively than either intervention alone.

To improve your insulin sensitivity, combining an 8-hour eating window with regular moderate aerobic exercise is more effective than doing either one alone. This approach helps lower insulin levels and improve insulin resistance markers more significantly than diet or exercise in isolation.

Semaglutide 2.4 mg weekly produces substantial and durable weight loss (10-15%) in adults with overweight or obesity through central appetite suppression, delayed gastric emptying, and improved glucose homeostasis.

If you have obesity, semaglutide 2.4 mg taken once weekly is a highly effective treatment for significant weight loss (10-15%). It works by reducing appetite and slowing digestion. Start with a low dose to minimize stomach upset, which usually improves over time. It is a long-term commitment, not a quick fix.

Dietary intake of fermentable fibers and prebiotics boosts the abundance of SCFA-producing bacteria (e.g., Bifidobacteria, Lachnospiraceae), leading to increased production of short-chain fatty acids (SCFAs) which regulate gut homeostasis, immunity, and metabolic health.

To improve your gut health and metabolic markers, focus on eating foods that feed your good bacteria. This means consuming prebiotic fibers found in foods like garlic, onions, bananas, oats, and resistant starches (like cooled potatoes or rice). This fosters bacteria that produce beneficial short-chain fatty acids, which support your gut barrier, immune system, and metabolism. Direct SCFA supplements have shown mixed results in humans, so diet is the primary lever.

A ketogenic diet (KD) improves glycemic control and insulin sensitivity in patients with Type 2 Diabetes Mellitus (T2DM) by reducing carbohydrate intake, lowering serum insulin, and enhancing fat catabolism.

For T2DM patients, adopting a ketogenic diet can significantly lower blood sugar and HbA1c levels compared to standard low-calorie diets. This is achieved by restricting carbohydrates, which lowers insulin levels and improves insulin sensitivity. However, medical supervision is critical, especially if you are taking insulin or SGLT2 inhibitors, to avoid dangerous side effects like hypoglycemia or ketoacidosis.

Insufficient sleep duration (less than 7 hours) disrupts hormonal regulation of appetite by decreasing leptin and increasing ghrelin, leading to increased caloric intake, preference for high-calorie foods, and higher risk of obesity.

Prioritize getting 7-9 hours of sleep. If you are sleep-deprived, you are biologically predisposed to eat more and crave high-calorie foods due to hormonal shifts (low leptin, high ghrelin). Fixing sleep is often more effective for weight management than dieting alone.

African American women with obesity and low insulin sensitivity lose significantly more fat mass and maintain higher total energy expenditure when following a low-carbohydrate diet compared to a low-fat diet.

If you are an African American woman with obesity and have struggled to lose weight on standard low-fat diets, switching to a low-carbohydrate approach (around 20% carbs, 55% fat) may help you lose more fat and keep your metabolism higher. This benefit is specifically linked to having lower insulin sensitivity, which is common in this demographic. Focus on whole foods, complex carbohydrates, and healthy fats while maintaining a caloric deficit.

Early time-restricted feeding (eTRF), defined as an 8-hour eating window between 06:00 and 15:00, significantly improves insulin sensitivity, reduces fasting glucose, lowers body mass and adiposity, and reduces inflammation in healthy non-obese adults compared to ad libitum eating.

If you are healthy and not obese, try eating all your meals within an 8-hour window that ends by 3 PM (e.g., 7 AM to 3 PM). You do not need to count calories or restrict food types, just the timing. This specific timing window has been shown to improve insulin sensitivity and reduce body fat more effectively than eating later in the day or eating whenever you want.

Regular moderate-intensity physical activity improves sleep quality and reduces sleep disorders (e.g., insomnia) in adults, with benefits observed across age groups including children and the elderly.

Aim for 30 minutes of moderate-intensity exercise, three times a week. This is the most effective dose for improving sleep quality and managing insomnia. If you are short on time, even 10 minutes of light morning exercise can provide benefits. Avoid high-intensity exercise within 3 hours of bedtime, as it may disrupt sleep.

Vigorous aerobic exercise improves body composition, cardiorespiratory fitness, and insulin resistance in women with PCOS, whereas resistance training and combined aerobic-resistance interventions show inconsistent or no significant benefits on these specific metabolic markers.

For PCOS management, prioritize vigorous aerobic exercise (like brisk walking, cycling, or swimming) for at least 75-150 minutes per week. This specific modality has the strongest evidence for improving insulin resistance and body composition. Resistance training alone may not provide the same metabolic benefits, so use it as a supplement, not a replacement, for aerobic activity.

Tirzepatide 15 mg once weekly produces significantly greater fat mass reduction and total body weight loss compared to semaglutide 1 mg and placebo in people with type 2 diabetes, primarily driven by fat mass rather than fat-free mass changes.

If you have type 2 diabetes, tirzepatide 15 mg taken once weekly is more effective than semaglutide 1 mg for reducing body fat and total weight. The weight loss comes mainly from fat, preserving muscle mass better than placebo. This suggests that for T2D patients seeking significant fat loss, tirzepatide may be a superior pharmacological option to semaglutide.

Tirzepatide at 15 mg and maximum tolerated dose (MTD) provides superior weight loss efficacy compared to semaglutide (2.4 mg and MTD) in non-diabetic adults with obesity, but this benefit is offset by significantly higher rates of gastrointestinal side effects and treatment discontinuation.

If you are a non-diabetic adult with obesity seeking maximum weight loss, tirzepatide at 15mg or MTD is statistically more effective than semaglutide. However, you must accept a higher risk of gastrointestinal side effects and a higher chance of stopping the medication due to those side effects. Discuss your tolerance for potential side effects versus the desire for maximum weight loss with your provider.

Subcutaneous semaglutide (up to 2.4 mg weekly) produces a mean weight reduction of 11.85% in adults with obesity without diabetes compared to placebo, though it significantly increases the risk of gastrointestinal adverse events and treatment discontinuation.

If you have obesity without diabetes, semaglutide (up to 2.4 mg weekly) can help you lose about 12% of your body weight, which is significantly more than placebo. However, you must be prepared for a high likelihood of temporary stomach issues like nausea or diarrhea. These side effects are common but usually mild and go away. You will also need to follow a reduced-calorie diet and exercise plan alongside the medication for best results.

Semaglutide significantly reduces Major Adverse Cardiovascular Events (MACE) and hospitalization for heart failure (HHF) risk, while Tirzepatide significantly reduces HHF risk, offering cardiovascular protection beyond weight loss.

If you have obesity and cardiovascular disease or heart failure, Semaglutide and Tirzepatide are not just weight loss drugs; they offer proven cardiovascular protection. Semaglutide reduces the risk of major heart events, and Tirzepatide reduces hospitalizations for heart failure. These benefits are independent of, but additive to, the weight loss achieved.

Weight loss triggers compensatory metabolic adaptations (hormonal and energy expenditure changes) that promote weight regain, making long-term maintenance difficult.

Expect that maintaining weight loss will be biologically challenging. Your body will fight back with increased hunger and decreased energy expenditure. This is normal and not your fault. Long-term success requires ongoing strategies to manage these biological drivers, such as regular self-monitoring and possibly higher protein intake to combat hunger hormones.

The weight loss efficacy of Tirzepatide is dose-dependent and increases with longer duration of treatment.

If you are taking Tirzepatide, sticking with the treatment for a longer duration and reaching the higher maintenance doses (like 15mg) will result in more significant weight loss than lower doses. The drug's effectiveness scales with the dose.

Obesity accelerates the loss of pancreatic beta-cell function and insulin sensitivity through ectopic adipose expansion, systemic low-grade inflammation, and lipotoxicity, leading to Type 2 Diabetes Mellitus (T2DM).

Obesity is not just about weight; it actively damages the body's ability to use insulin and produce it via inflammation and fat accumulation in organs like the liver and pancreas. Managing obesity is critical to preventing or delaying T2DM, but it requires addressing metabolic health, not just scale weight.